Ressources
-
STORM Therapeutics: From Lead to Pre-Candidate Nomination in 18 Months
STORM Therapeutics: From Lead to Pre-Candidate Nomination in 18 Months
Case study
Search Results
Search across news, resources and pages to quickly find relevant content on our site.
Case Studies
The Challenge Clients sometimes as us to generate Fab and Fc pools from a full-length…
Technical Notes
Discover precise insights into brain neurochemistry with Sygnature Discovery's in vivo microdialysis and cOFM services. With over 20 years of expertise, we design bespoke studies that reveal how compounds modulate neurotransmitter systems in health and disease. Using UHPLC/HPLC with electrochemical detection or mass spectrometry, we deliver robust PK/PD data to support confident CNS decision making.
Journal Papers
Ting Qin, Aparna Chandrasekaran, Jack Hoffman, Jason Shiers, Tarun Jain, Colin Sambrook Smith Abstract Artificial intelligence (AI) holds…
Case Studies
In this case study we present how we have evolved and developed a robust analytical…
Case Studies
In this case study we demonstrate Sygnature Discovery’s ability to provide a complete, end‑to‑end Antibody…
Blog
Celebrating 10 glorious years of working with HEK293-6E cells to produce high quality recombinant proteins…
Case Studies
A client had requested to obtain a small peptide that was <10kDa, normally processed by…
Case Studies
One SEC run, Two fluorescence readouts, highlighting the “Sygnature” peaks with your target protein.
Journal Papers
Tatiana Rosado Rosenstock, Hiromitsu Ohzeki, Shohei Kumagai, Natsuno Suda, Colin Sambrook Smith Abstract Target identification (Target ID) is a foundational, multi-disciplinary…
Blog
Drug addiction remains one of the most persistent and complex public health challenges worldwide. Despite advances in prevention and treatment, drug‑related harm and mortality continue to rise, underscoring the need for deeper biological understanding and more predictive models to support the development of new therapies.
Blog
Focusing on the intoxication phase of addiction, this article examines how behavioral pharmacology models capture reward, reinforcement and binge‑like drug use in preclinical studies.
Blog
Focusing on the withdrawal phase of addiction, this article examines how behavioral pharmacology models assess drug dependence and therapeutic intervention in preclinical studies.
Blog
Focusing on the craving phase of addiction, this article examines how behavioral pharmacology models capture cue‑driven drug seeking and relapse vulnerability.
Journal Papers
Francesca Marano, Callum McKenzie, James R. Birtley, Sadaf A. Hussain, Olivia Macleod, Alexander Goodacre,…
Case Studies
We were asked by Greywolf Therapeutics to provide support for an endoplasmic reticulum aminopeptidase-1 (ERAP1)…
Case Studies
“An Effective Solution for Labelling when Protein Folding is a Challenge” In this case study…
Case Studies
Our journey started, as it often does, with an X-ray crystallography project which looked…
Technical Notes
Why model choice has become a data-driven discipline, and how we can support it with platforms such as DepMap, GTEx, and Open Targets
Webinars & Podcasts
In drug discovery, generating targets is no longer the challenge.
The real question is how to identify the few worth investing months of research and significant resources to pursue.
Hear expert perspectives on how AI, pathway analysis and scientific expertise are shaping modern target identification.
Case Studies
In this short case study, we present how our legendary Form & Formulation (F&F) team…
Case Studies
Projects often have different priorities such as budget constraints,…
Support
Can't find what you're looking for?
Can't find what you're looking for? Our team can help — whether you need assistance locating a resource, have a research enquiry, or want media information, get in touch and we'll point you in the right direction.
